Research programme: NLRP3 antagonists - Novartis
Alternative Names: IFM-514Latest Information Update: 28 Dec 2022
At a glance
- Originator IFM therapeutics
- Developer Novartis; University of Bonn
- Class Anti-inflammatories; Antidementias; Small molecules
- Mechanism of Action NLRP3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease; Inflammatory bowel diseases; Non-alcoholic steatohepatitis
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in Germany (Intraperitoneal, Injection)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 28 Aug 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA